secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2024-09-09T23:59:59+00:00
Accession:  0001104659-24-097969
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts partial clinical holds on Rezolute's RZ358 for congenital hyperinsulinism
--------------------------------------------------------------------------------

- FDA removed partial clinical holds on RZ358 (ersodetug) for hypoglycemia in congenital HI; U.S. enrollment in global Phase 3 sunRIZE study now permitted.
- FDA concluded liver toxicity in Sprague Dawley rats is strain-specific and not relevant to humans.
- Company expects to begin U.S. participant enrollment in early 2025; topline data from sunRIZE study anticipated in H2 2025.
- This follows prior FDA clearance of a separate Phase 3 study in tumor-associated HI, advancing ersodetug in two rare disease programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924097969/0001104659-24-097969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924097969/tm2420844d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-097969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer